Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

9.975 -1.135 (-10.22%)
Streaming Delayed Price Updated: 11:13 AM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Seres Therapeutics' Q2 Revenues Top Estimates; Reports Encouraging VOWST Early Commercial Uptake
Seres Therapeutics, Inc. (NASDAQ: MCRB) reported Q2 revenues of $126.47 million,  
Via Benzinga
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Tuesday. Here are some big stocks recording gains in today’s session. Paymentus Holdings, Inc. (NYSE: PAY) shares rose 29.4% to... 
Via Benzinga
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Earnings Outlook For Seres Therapeutics
Via Benzinga
Looking Into Seres Therapeutics's Return On Capital Employed
Via Benzinga
Preview: Seres Therapeutics's Earnings
Via Benzinga
Where Seres Therapeutics Stands With Analysts
Via Benzinga
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023
From Seres Therapeutics, Inc.
Via Business Wire
Why Seres Therapeutics Shares Are Surging Thursday Morning
Via Benzinga
'Walk Away From It': Jim Cramer On This US Telecom Service Provider
On CNBC’s "Mad Money Lightning Round," Jim Cramer said AT&T Inc. (NYSE: T) is "as poorly managed as any company I’ve ever seen in my lifetime." He added, 
Via Benzinga
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Named to TIME100 Most Influential Companies List
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at Jefferies Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023
From Seres Therapeutics, Inc.
Via Business Wire
Mastercard To Rally Over 18%? Here Are 10 Other Analyst Forecasts For Friday
Wells Fargo raised the price target for Molina Healthcare, Inc. (NYSE: MOH) from $282 to $290. Wells Fargo analyst Stephen Baxter maintained an Underweight rating. Molina Healthcare shares gained 7.8%... 
Via Benzinga
Snap, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree
From Seres Therapeutics, Inc.
Via Business Wire
Tesla, Meta Platforms, Seres Therapeutics, Atomera, Roku: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
From Seres Therapeutics, Inc. and Nestlé Health Science
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.